Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HARSHAD V AMIN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1679807242
CMS profile
724624
Location
PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$27,809.40

253 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HARSHAD V AMIN

NPI 1679807242 · CMS profile ID 724624

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

253 matching records · $27,809.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 253 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–253 of 253.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4401/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721000421 CMS
Seagen Inc. $95.0001/03/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732456455 CMS
Janssen Pharmaceuticals, Inc $13.4301/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719165131 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $62,902.55 346
PY2020 $27,809.40 253
PY2021 $28,729.36 260
PY2022 $19,029.54 276
PY2023 $9,733.92 295
PY2024 $6,201.88 276
PY2025 $4,717.87 239

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $631,397.59 109
PY2024 Principal investigator $843,986.12 92
PY2023 Principal investigator $838,551.38 209
PY2022 Principal investigator $583,428.39 93
PY2021 Principal investigator $405,294.96 86
PY2020 Principal investigator $291,165.08 83
PY2019 Principal investigator $148,284.54 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

109 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $11,200.95 12/31/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228747672
Principal investigator 1 PFIZER INC. $9,722.70 12/12/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228731942
Principal investigator 1 SANOFI US SERVICES INC. $2,668.40 12/08/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091238
Principal investigator 1 GlaxoSmithKline, LLC. $5,468.85 11/21/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146813
Principal investigator 1 PFIZER INC. $4,750.00 11/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228738135
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 11/12/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211415001
Principal investigator 1 SANOFI US SERVICES INC. $193.70 11/10/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091226
Principal investigator 1 PFIZER INC. $9,289.20 11/04/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228730135
Principal investigator 1 Amgen Inc. $750.00 10/24/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246639789
Principal investigator 1 PFIZER INC. $1,200.00 10/21/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228741933
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 10/14/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091204
Principal investigator 1 PFIZER INC. $6,425.35 10/08/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228741047
Principal investigator 1 SANOFI US SERVICES INC. $6,930.00 10/06/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091193
Principal investigator 1 TAIHO ONCOLOGY, INC. $140.00 10/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1211416458
Principal investigator 1 Amgen Inc. $1,350.00 09/23/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246639793
Principal investigator 1 SANOFI US SERVICES INC. $1,200.00 09/22/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091182
Principal investigator 1 PFIZER INC. $660.00 09/16/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228771240
Principal investigator 1 SANOFI US SERVICES INC. $160.00 09/15/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091167
Principal investigator 1 SANOFI US SERVICES INC. $11,362.40 09/15/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091171
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 09/12/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144561
Principal investigator 1 PFIZER INC. $1,216.35 09/03/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228750589
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 08/22/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211416460
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 08/22/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211418567
Principal investigator 1 Merck Sharp & Dohme LLC $34,760.00 08/11/2025 Non-covered Recipient Entity
Boca Raton Cancer Research Global, BRCR Global
A Phase I,II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors No dispute reported 06/30/2026 1232932603
Principal investigator 1 SANOFI US SERVICES INC. $10,711.40 08/11/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091139
Principal investigator 1 PFIZER INC. $1,262.25 08/02/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228768200
Principal investigator 1 PFIZER INC. $1,675.35 07/30/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228720283
Principal investigator 1 PFIZER INC. $600.00 07/16/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228783529
Principal investigator 1 SANOFI US SERVICES INC. $7,900.00 07/14/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091485
Principal investigator 1 SANOFI US SERVICES INC. $10,711.40 07/07/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091129
Principal investigator 1 PFIZER INC. $1,740.15 06/27/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228774887
Principal investigator 1 GlaxoSmithKline, LLC. $1,755.00 06/22/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146834
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 06/16/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091475
Principal investigator 1 TAIHO ONCOLOGY, INC. $486.53 06/16/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415011
Principal investigator 1 TAIHO ONCOLOGY, INC. $717.00 06/16/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211417843
Principal investigator 1 TAIHO ONCOLOGY, INC. $54.06 06/16/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211420009
Principal investigator 1 PFIZER INC. $3,850.00 06/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228777271
Principal investigator 1 PFIZER INC. $1,800.00 06/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228791875
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415013
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415015
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,000.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211415776
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211416466
Principal investigator 1 TAIHO ONCOLOGY, INC. $153.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211416468
Principal investigator 1 TAIHO ONCOLOGY, INC. $153.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211416470
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,215.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211417845
Principal investigator 1 TAIHO ONCOLOGY, INC. $153.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211417847
Principal investigator 1 TAIHO ONCOLOGY, INC. $153.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211418573
Principal investigator 1 TAIHO ONCOLOGY, INC. $153.00 06/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 1211418575
Principal investigator 1 SANOFI US SERVICES INC. $11,362.40 06/09/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091471
Principal investigator 1 GlaxoSmithKline, LLC. $17.70 06/03/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144574
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 06/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146837
Principal investigator 1 PFIZER INC. $11,138.70 05/30/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228765591
Principal investigator 1 GlaxoSmithKline, LLC. $2,015.55 05/29/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148031
Principal investigator 1 SANOFI US SERVICES INC. $244.80 05/19/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091479
Principal investigator 1 Exelixis Inc. $2,542.00 05/13/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379826
Principal investigator 1 Exelixis Inc. $954.00 05/13/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379828
Principal investigator 1 Exelixis Inc. $4,500.00 05/13/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379830
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,207.34 05/09/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416464
Principal investigator 1 SANOFI US SERVICES INC. $10,711.40 05/05/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091440
Principal investigator 1 GlaxoSmithKline, LLC. $2,631.15 05/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144565
Principal investigator 1 PFIZER INC. $500.00 04/29/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228723514
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 04/28/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144569
Principal investigator 1 GlaxoSmithKline, LLC. $5,468.85 04/28/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144579
Principal investigator 1 GlaxoSmithKline, LLC. $1,890.00 04/28/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146817
Principal investigator 1 PFIZER INC. $2,462.40 04/25/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228794605
Principal investigator 1 PFIZER INC. $3,000.00 04/24/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228779687
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 04/14/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091429
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 04/14/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211415009
Principal investigator 1 TAIHO ONCOLOGY, INC. $500.00 04/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211420005
Principal investigator 1 PFIZER INC. $722.25 04/05/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228779830
Principal investigator 1 SANOFI US SERVICES INC. $10,711.40 04/02/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091387
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 04/01/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211417841
Principal investigator 1 PFIZER INC. $15,886.80 03/22/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228782763
Principal investigator 1 GlaxoSmithKline, LLC. $5,468.85 03/21/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146821
Principal investigator 1 GlaxoSmithKline, LLC. $5,468.85 03/21/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148045
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 03/21/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211416462
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 03/19/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211415003
Principal investigator 1 SANOFI US SERVICES INC. $11,606.00 03/17/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091372
Principal investigator 1 PFIZER INC. $500.00 03/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228782788
Principal investigator 1 PFIZER INC. $600.00 03/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER No dispute reported 06/30/2026 1228796324
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 03/11/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192144558
Principal investigator 1 GlaxoSmithKline, LLC. $9,997.09 03/06/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148040
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 03/06/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211420003
Principal investigator 1 SANOFI US SERVICES INC. $320.00 03/04/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091306
Principal investigator 1 GlaxoSmithKline, LLC. $2,340.90 02/27/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146809
Principal investigator 1 Amgen Inc. $5,300.00 02/22/2025 Non-covered Recipient Entity
BOCA RATON CLINICAL RESEARCH GLOBAL SOUTH FLORIDA
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) No dispute reported 06/30/2026 1246639755
Principal investigator 1 TAIHO ONCOLOGY, INC. $500.00 02/20/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211417839
Principal investigator 1 SANOFI US SERVICES INC. $10,781.40 02/18/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091318
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 02/18/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091323
Principal investigator 1 PFIZER INC. $5,875.35 02/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228769769
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,145.40 02/14/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211418571
Principal investigator 1 Exelixis Inc. $4,725.00 02/07/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379822
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 02/07/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146829
Principal investigator 1 GlaxoSmithKline, LLC. $4,740.77 02/05/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148027
Principal investigator 1 SANOFI US SERVICES INC. $650.00 02/04/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091341
Principal investigator 1 Amgen Inc. $236,284.52 01/27/2025 Non-covered Recipient Entity
BOCA RATON CLINICAL RESEARCH GLOBAL SOUTH FLORIDA
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy No dispute reported 06/30/2026 1246639753
Principal investigator 1 SANOFI US SERVICES INC. $10,711.40 01/27/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091335
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,145.40 01/27/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211418569
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,023.83 01/27/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) No dispute reported 06/30/2026 1211419257
Principal investigator 1 TAIHO ONCOLOGY, INC. $600.00 01/24/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211419261
Principal investigator 1 Exelixis Inc. $675.00 01/20/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222379824
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 01/16/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192146825
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 01/16/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148035
Principal investigator 1 PFIZER INC. $2,397.60 01/15/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 No dispute reported 06/30/2026 1228800081
Principal investigator 1 TAIHO ONCOLOGY, INC. $14,130.19 01/15/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211415007
Principal investigator 1 TAIHO ONCOLOGY, INC. $6,082.29 01/10/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211419259
Principal investigator 1 GlaxoSmithKline, LLC. $8,100.59 01/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P No dispute reported 06/30/2026 1192148050
Principal investigator 1 TAIHO ONCOLOGY, INC. $3,071.49 01/06/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211420007
Principal investigator 1 TAIHO ONCOLOGY, INC. $9,631.08 01/03/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
ASTX727-07 No dispute reported 06/30/2026 1211415005